Analytical method lifecycle management for complex modalities Analytical Method Lifecycle Management for Complex Modalities Context The regulatory landscape for complex products, including sterile injectables, inhalation products, and advanced therapy medicinal products (ATMPs), presents unique challenges for CMC (Chemistry, Manufacturing and Controls) professionals. As these modalities grow in complexity, so do the regulations and guidelines governing their development and commercialization. Understanding the analytical method lifecycle management associated with these products is crucial for ensuring compliance with FDA, EMA, and MHRA expectations. Legal/Regulatory Basis The lifecycle of analytical methods used in the CMC segment for complex products is guided by several key…

Global CMC expectations for complex products across major agencies CMC Lifecycle Management for Complex Products: Regulatory Expectations Across Major Agencies Context Regulatory Affairs (RA) professionals face increasing complexities in the development and approval of combination products, sterile injectables, inhalation products, and Advanced Therapy Medicinal Products (ATMPs). The intricate manufacturing processes and specialized CMC (Chemistry, Manufacturing, and Controls) requirements present unique challenges that necessitate a thorough understanding of the regulatory framework, agency expectations, and technical guidelines established in the US, EU, and UK. Legal/Regulatory Basis The regulatory landscape for CMC focuses on ensuring the quality, safety, and efficacy of complex products…

Scaling manufacturing for complex injectables without losing control Scaling Manufacturing for Complex Injectables Without Losing Control Regulatory Affairs Context In the pharmaceutical and biotechnology industries, chemistry, manufacturing, and controls (CMC) for complex products such as sterile injectables, inhalation products, and advanced therapy medicinal products (ATMPs) present unique challenges. Regulatory affairs (RA) professionals need to navigate a complex landscape of guidelines and expectations defined by regulatory authorities like the FDA (U.S.), EMA (Europe), and MHRA (U.K.). This article serves as a detailed regulatory explainer manual to help professionals manage the CMC lifecycle effectively, ensuring compliance while scaling up manufacturing operations. Legal/Regulatory…

Platform versus Bespoke CMC Approaches for Advanced Modalities Platform versus Bespoke CMC Approaches for Advanced Modalities Context In the rapidly evolving landscape of pharmaceutical development, the manufacturing and control (CMC) of complex products such as sterile injectables, inhalation products, and advanced therapy medicinal products (ATMPs) presents unique challenges. Regulatory Affairs (RA) professionals must be adept in determining the most suitable approaches for CMC development. Two primary strategies exist in CMC: platform approach and bespoke approach. Choosing between these can significantly influence regulatory strategy and ultimately affect product approval success. This article delineates these approaches within the context of regulatory expectations…

Tech transfer strategies for complex dosage forms and ATMPs Tech Transfer Strategies for Complex Dosage Forms and ATMPs Context In the ever-evolving landscape of pharmaceutical development, regulatory affairs (RA) professionals play a pivotal role, especially concerning the chemistry, manufacturing, and controls (CMC) of complex products such as injectables, inhalation therapies, and advanced therapy medicinal products (ATMPs). These dosage forms present unique challenges and necessitate thorough understanding and strategic planning during tech transfer processes. This article serves as a comprehensive regulatory explainer manual detailing the overarching regulations, guidelines, and core principles driving the tech transfer of complex dosage forms and ATMPs…

Inspection readiness focus areas for complex product CMC programs Inspection Readiness Focus Areas for Complex Product CMC Programs In the rapidly evolving landscape of pharmaceutical and biotech development, ensuring compliance with regulatory expectations for complex products, such as sterile injectables, inhalation products, advanced therapy medicinal products (ATMPs), and combination products, is critical. As CMC (Chemistry, Manufacturing, and Controls) professionals navigate these challenges, understanding the legal and regulatory framework is essential for achieving inspection readiness. Regulatory Affairs Context Regulatory Affairs (RA) plays a pivotal role in ensuring that pharmaceutical and biotech products meet the required regulatory standards set forth by national…

Cost optimisation strategies across the CMC lifecycle without risking compliance Cost optimisation strategies across the CMC lifecycle without risking compliance Context The cost of developing pharmaceutical products is continuously rising, yet regulatory demands remain stringent. As such, the need for effective CMC cost optimisation outsourcing strategies is paramount. This manual aims to provide regulatory professionals with a thorough understanding of the considerations, regulations, and best practices for optimising costs in the Chemistry, Manufacturing, and Controls (CMC) lifecycle while ensuring compliance with FDA, EMA, and MHRA guidelines. Legal/Regulatory Basis Numerous regulations govern the CMC lifecycle across different regions, most notably: 21…

When to outsource CMC activities and when to keep them in house When to Outsource CMC Activities and When to Keep Them In-House Regulatory Affairs Context In the pharmaceutical and biotechnology industries, the management of Chemistry, Manufacturing, and Controls (CMC) is critical for ensuring compliance with regulatory requirements established by agencies such as the FDA, European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA). The decision to outsource CMC activities or to maintain these functions in-house is influenced by various factors, including regulatory expectations, cost considerations, and operational efficiencies. This article serves as a comprehensive guide…

Designing a hybrid CMC operating model with CDMOs and internal teams Designing a hybrid CMC operating model with CDMOs and internal teams Introduction In the context of pharmaceutical manufacturing, the integration of Contract Development and Manufacturing Organizations (CDMOs) into the Chemistry, Manufacturing, and Controls (CMC) lifecycle has become increasingly prevalent. This method not only enhances efficiency but also optimizes costs, ensuring that companies remain competitive in a fast-evolving market. Given the regulatory complexities that govern the pharmaceutical industry, it is imperative to design a hybrid CMC operating model that balances the engagement with CDMOs and internal capabilities. Regulatory Context The…

Total cost of ownership analysis for CMC outsourcing decisions Total Cost of Ownership Analysis for CMC Outsourcing Decisions The landscape of pharmaceutical and biotechnology industries is dynamic and increasingly competitive. Within this context, the importance of effective Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) partnerships has come to the forefront, especially in the realm of Chemistry, Manufacturing, and Controls (CMC) lifecycle management. This article is a comprehensive regulatory explainer manual aimed at providing Kharma and regulatory professionals with an in-depth understanding of the total cost of ownership (TCO) analysis relevant to CMC outsourcing decisions. Context CMC…